(OM) Outset Medical - Ratings and Ratios
Portable, Home, Hemodialysis, Machine
OM EPS (Earnings per Share)
OM Revenue
Description: OM Outset Medical
Outset Medical, Inc. (NASDAQ:OM) is a medical technology company that has developed the Tablo Hemodialysis System, a compact and innovative solution for hemodialysis treatment. The system integrates water purification, on-demand dialysate production, and advanced software and connectivity capabilities, making it a comprehensive solution for healthcare providers.
The companys product portfolio includes the Tablo console, Tablo cartridge, and other consumables, which are manufactured, supported, and distributed by Outset Medical. Additionally, the company offers the Tablo Data Ecosystem, a suite of digital platforms that provide valuable insights and data analytics to healthcare providers, patients, and internal stakeholders. This ecosystem includes TabloHub, MyTablo, and TabloDash, which facilitate data-driven decision-making and patient care.
From a financial perspective, Outset Medicals revenue growth and operating expenses are key performance indicators (KPIs) to monitor. The companys ability to scale its business while maintaining a strong gross margin is crucial to its long-term success. Other important KPIs include the number of Tablo systems installed, patient adoption rates, and the companys cash burn rate. With a market capitalization of $364.72M USD, Outset Medicals financial performance will be closely watched by investors.
In terms of key metrics, investors should also track the companys research and development (R&D) pipeline, regulatory updates, and competitive landscape. The hemodialysis market is highly competitive, and Outset Medicals ability to innovate and differentiate its products will be essential to its success. By monitoring these KPIs and staying informed about the companys progress, investors can make more informed decisions about their investment in Outset Medical, Inc.
OM Stock Overview
| Market Cap in USD | 244m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2020-09-15 |
OM Stock Ratings
| Growth Rating | -30.0% |
| Fundamental | 14.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 47.5% |
| Analyst Rating | 4.20 of 5 |
OM Dividends
Currently no dividends paidOM Growth Ratios
| Growth Correlation 3m | -78.3% |
| Growth Correlation 12m | 55.4% |
| Growth Correlation 5y | -94.4% |
| CAGR 5y | -62.29% |
| CAGR/Max DD 3y | -0.63 |
| CAGR/Mean DD 3y | -0.71 |
| Sharpe Ratio 12m | -0.69 |
| Alpha | 0.00 |
| Beta | 0.990 |
| Volatility | 91.25% |
| Current Volume | 183.6k |
| Average Volume 20d | 124.3k |
| Stop Loss | 13.1 (-6%) |
| Signal | 0.55 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-97.9m TTM) > 0 and > 6% of Revenue (6% = 7.16m TTM) |
| FCFTA -0.41 (>2.0%) and ΔFCFTA 2.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 200.1% (prev 216.2%; Δ -16.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.23 (>3.0%) and CFO -67.5m > Net Income -97.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (17.7m) change vs 12m ago 413.0% (target <= -2.0% for YES) |
| Gross Margin 36.46% (prev 28.23%; Δ 8.23pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.55% (prev 37.02%; Δ 2.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.47 (EBITDA TTM -60.9m / Interest Expense TTM 18.9m) >= 6 (WARN >= 3) |
Altman Z'' -17.73
| (A) 0.83 = (Total Current Assets 275.6m - Total Current Liabilities 36.9m) / Total Assets 288.8m |
| (B) -3.93 = Retained Earnings (Balance) -1.13b / Total Assets 288.8m |
| warn (B) unusual magnitude: -3.93 — check mapping/units |
| (C) -0.22 = EBIT TTM -65.8m / Avg Total Assets 301.7m |
| (D) -8.46 = Book Value of Equity -1.13b / Total Liabilities 134.0m |
| Total Rating: -17.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 14.32
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -74.78% = -5.0 |
| 3. FCF Margin -98.25% = -7.50 |
| 4. Debt/Equity 0.62 = 2.31 |
| 5. Debt/Ebitda -1.59 = -2.50 |
| 6. ROIC - WACC (= -34.70)% = -12.50 |
| 7. RoE -98.08% = -2.50 |
| 8. Rev. Trend -26.86% = -2.01 |
| 9. EPS Trend -49.53% = -2.48 |
What is the price of OM shares?
Over the past week, the price has changed by +2.88%, over one month by +1.90%, over three months by -26.45% and over the past year by +74.86%.
Is Outset Medical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OM is around 7.66 USD . This means that OM is currently overvalued and has a potential downside of -45.01%.
Is OM a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the OM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.8 | 84.9% |
| Analysts Target Price | 25.8 | 84.9% |
| ValueRay Target Price | 8.5 | -39.1% |
Last update: 2025-09-04 04:44
OM Fundamental Data Overview
CCE Cash And Equivalents = 184.1m USD (Cash And Short Term Investments, last quarter)
P/S = 2.0461
P/B = 1.6372
Beta = 2.137
Revenue TTM = 119.3m USD
EBIT TTM = -65.8m USD
EBITDA TTM = -60.9m USD
Long Term Debt = 94.8m USD (from longTermDebt, last quarter)
Short Term Debt = 1.91m USD (from shortTermDebt, last quarter)
Debt = 96.7m USD (Calculated: Short Term 1.91m + Long Term 94.8m)
Net Debt = -35.9m USD (from netDebt column, last quarter)
Enterprise Value = 156.7m USD (244.1m + Debt 96.7m - CCE 184.1m)
Interest Coverage Ratio = -3.47 (Ebit TTM -65.8m / Interest Expense TTM 18.9m)
FCF Yield = -74.78% (FCF TTM -117.2m / Enterprise Value 156.7m)
FCF Margin = -98.25% (FCF TTM -117.2m / Revenue TTM 119.3m)
Net Margin = -82.06% (Net Income TTM -97.9m / Revenue TTM 119.3m)
Gross Margin = 36.46% ((Revenue TTM 119.3m - Cost of Revenue TTM 75.8m) / Revenue TTM)
Tobins Q-Ratio = -0.14 (set to none) (Enterprise Value 156.7m / Book Value Of Equity -1.13b)
Interest Expense / Debt = 3.59% (Interest Expense 3.48m / Debt 96.7m)
Taxrate = 21.0% (US default)
NOPAT = -65.8m (EBIT -65.8m, no tax applied on loss)
Current Ratio = 7.47 (Total Current Assets 275.6m / Total Current Liabilities 36.9m)
Debt / Equity = 0.62 (Debt 96.7m / last Quarter total Stockholder Equity 154.8m)
Debt / EBITDA = -1.59 (Net Debt -35.9m / EBITDA -60.9m)
Debt / FCF = -0.83 (Debt 96.7m / FCF TTM -117.2m)
Total Stockholder Equity = 99.8m (last 4 quarters mean)
RoA = -33.90% (Net Income -97.9m, Total Assets 288.8m )
RoE = -98.08% (Net Income TTM -97.9m / Total Stockholder Equity 99.8m)
RoCE = -33.79% (Ebit -65.8m / (Equity 99.8m + L.T.Debt 94.8m))
RoIC = -26.98% (NOPAT -65.8m / Invested Capital 243.8m)
WACC = 7.72% (E(244.1m)/V(340.8m) * Re(9.66%)) + (D(96.7m)/V(340.8m) * Rd(3.59%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 90.91 | Cagr: 16.82%
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -117.2m)
EPS Correlation: -49.53 | EPS CAGR: 0.07% | SUE: 0.16 | # QB: 0
Revenue Correlation: -26.86 | Revenue CAGR: 4.60% | SUE: 1.12 | # QB: 2
Additional Sources for OM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle